FOR VETERINARY USE ONLY

Resolid CAT

COMBINED LIVE ATTENUATED VACCINE AGAINST
RHINOTRACHEITIS, CALICIVIROSIS AND PANLEUKOPENIA

Dollvet

LYOPHILISATE FOR SUSPENSION FOR INJECTION AND SOLVENT

COMPOSITION:

Each single dose of the vaccine contains the following components:

Lyophilisate for Suspension for Injection

Active ingredients	Amount	Function
Attenuated Feline calicivirus F9 strain	$\geq 10^{4,6}$ TCID50/dose*	Immunising antigen
Attenuated Feline herpesvirus type 1 FVRm strain	$\geq 10^{5,2}$ TCID50/dose*	
Attenuated Feline panleukopenia Philips-Roxane strain	$\geq 10^{4,0}$ FAID50/dose**	
Excipients		
Lactalbumin hydrolysate	0.25 mg/dose	Stabiliser
Sucrose	0.50 mg/dose	

*Tissue Culture Infective Dose
**Fluorescent Antibody Infective Dose

Dilution for parenteral administration

Components	Quantity	Function
Sodium chloride	8,5 mg/ml	Dilution buffer
Disodium hydrogen phosphate heptahydrate	0.18 mg/ml	
Sodium dihydrogen phosphate dihydrate	0.06 mg/ml	
Water for injections	q.s. to 1 ml	

IMMUNOLOGICAL PROPERTIES:

Pharmacotherapeutic group: Attenuated, lyophilised Feline calicivirus, Feline herpesvirus and Feline panleukopenia vaccine.
ATC Vet Code: QI06AD04
RESOLID CAT is an attenuated, lyophilised vaccine administered in cats for prophylactic purposes against viral rhinotracheitis caused by Feline herpesvirus type 1, calicivirosis caused by Feline calicivirus, and panleukopenia caused by Feline panleukopenia virus.

INDICATIONS:

RESOLID CAT is administered in cats for prophylactic purposes against viral rhinotracheitis caused by Feline herpesvirus type 1, calicivirosis caused by Feline calicivirus, and panleukopenia caused by Feline panleukopenia virus. Following the booster vaccination, an immune response is occured after 4 weeks for Feline calicivirus and Feline herpesvirus type 1, and after 3 weeks for Feline panleukopenia virus.
The duration of immunity is 1 year following vaccination.

METHOD OF ADMINISTRATION AND DOSAGE:

The solvent is added to the lyophilised pellet. The vaccine is slowly reconstituted to obtain a homogeneous suspension with limited foam formation. After reconstitution, a clear, pink-coloured suspension for injection is obtained. The product is withdrawn into a syringe and administered by the subcutaneous route at a dose of 1 ml to kittens from 8 weeks of age and to adult cats. For protective immunity, vaccination is performed twice at an interval of 4 weeks. Vaccination should be repeated annually.

CLINICAL PARTICULARS AND SPECIAL WARNINGS FOR TARGET SPECIES:

-Animals suspected of being infected or in the incubation period, as well as animals under stress, must not be vaccinated.
-When the vaccine is to be used, the lyophilized pellet should be completely reconstituted with the diluent using sterile syringes, and the vaccine vial should be gently shaken before use.
-Prior to administration, the vaccine should be brought to body temperature.
-During vaccination, the vaccine vial must be protected from direct sunlight.
-Aseptic needles and syringes must be used during administration.
-The vaccine must be administered only by a veterinarian or by veterinary health technicians under the supervision of a veterinarian.
Use during pregnancy and lactation: Use during pregnancy and lactation is not recommended.

ADVERSE REACTIONS:

Short-term local reactions at the injection site (such as redness, mild swelling, and scab formation) and a transient increase in body temperature may very commonly be observed in animals. Very rarely, anaphylactic reactions may develop in sensitive animals. In such cases, symptomatic treatment (antihistaminic/anti-allergic medicinal products) may be administered.

FOR VETERINARY USE ONLY

Resolid CAT

COMBINED LIVE ATTENUATED VACCINE AGAINST
RHINOTRACHEITIS, CALICIVIROSIS AND PANLEUKOPENIA

Dollvet

LYOPHILISATE FOR SUSPENSION FOR INJECTION AND SOLVENT

-Very common (more than 1 animal in 10)
-Common (more than 1 but fewer than 10 animals in 100)
-Uncommon (more than 1 but fewer than 10 animals in 1,000)
-Rare (more than 1 but fewer than 10 animals in 10,000)
-Very rare (fewer than 1 animal in 10,000)

INTERACTION WITH OTHER MEDICINAL PRODUCTS:
No information is available on the safety and efficacy of this vaccine when used with other biological products. Therefore, it has not been proven that using this product on the same day as other products or at different times is effective and reliable.

OVERDOSE, SYMPTOMS IF ANY, EMERGENCY PROCEDURES AND ANTIDOTES:
In safety studies, administration of a dose 10 times higher than the recommended normal dose was found to be safe

WITHDRAWAL PERIODS FOR FOOD-PRODUCING ANIMALS:
Not for use in food-producing animals.

CONTRAINDICATIONS:
It has no known contraindications.

GENERAL WARNINGS:
"Keep out of reach of children" "Consult your veterinarian before use and in case of an unexpected effect"

PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE VACCINE AND RECOMMENDATIONS FOR VETERINARIANS:
-There is no known adverse effect on human health: however, in the case of injuries that may occur during vaccine administration, the affected area should be cleaned and disinfected.
-In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

STORAGE CONDITIONS AND SHELF LIFE:
Lyophilisate for suspension for injection:
Store at 2–8°C and protect from light. Do not freeze.
Shelf life: 24 months.
Diluent for parenteral administration:
Store below 25°C, protected from light, without refrigeration. Do not freeze.
Shelf life: 24 months. The reconstituted vaccine should be used within 2 hours.

DISPOSAL OF WASTE AND RECOMMENDATIONS FOR NON-TARGET SPECIES:
Any unused product or waste materials derived from the use of this product should be disposed of in accordance with the relevant legislation.
All waste/residual materials must not be mixed with household waste or wastewater, and must not be discharged into drainage systems or the environment.

PRESENTATION:
The vaccine is packaged in 2R Type I colourless glass vials containing a single-dose lyophilised pellet, and in 1 ml 2R Type I colourless glass vials containing the diluent for parenteral administration. The glass vials are sealed with bromobutyl stoppers and aluminium caps and are appropriately labelled.
The product is placed on the market in plastic trays or boxes containing 10 × 1 dose lyophilised pellets and 10 × 1 ml diluent for parenteral administration.
Not all pack sizes may be marketed simultaneously.

LEAFLET APPROVAL DATE:14.10.2025
DATE OF MARKETING AUTHORIZATION ISSUED BY THE MINISTRY OF AGRICULTURE AND FORESTRY OF T.R.: 14.10.2025

NAME AND ADDRESS OF MARKETING AUTHORIZATION HOLDER:
DOLLVET BİYOTEKNOLOJİ A.Ş.
Konaklar Mahallesi Akasyalı Sokak No:10 Beşiktaş/İstanbul
E-mail: dollvet@dollvet.com.tr **Phone:** +90 212 422 02 01 **Fax:** +90 212 422 00 72
NAME AND ADDRESS OF MANUFACTURER:
DOLLVET BİYOTEKNOLOJİ A.Ş.
Organize Sanayi Bölgesi Koçören OSB Mahallesi 106. Cadde No:6 Eyyübiye/ŞANLIURFA
E-mail: dollvet@dollvet.com.tr **Phone:** +90 414 369 11 33 **Fax:** +90 414 369 16 62

201535-R.01